Investments will weigh on margins in 2022

The veterinary laboratory achieved its profitability objectives over the last financial year but remains cautious for the next one. The animal health specialist experienced a spectacular recovery last year, as confirmed by the publication in January of organic revenue growth of 18.4%. A dynamic driven by the companion animals division and the United States, which […]

Investments will weigh on margins in 2022 Read More »

The veterinary laboratory accelerated over the last financial year

The strategic refocusing of the animal health specialist on its most promising niches is a success, as evidenced by the annual accounts. Vetoquinol had already revealed an annual turnover of 521 million euros, gross growth of 21.9% including 13.7% organic. The difference between the two progressions is mainly explained by the integration of Drontal and

The veterinary laboratory accelerated over the last financial year Read More »

A much better dynamic than expected at the start of the financial year

A much better dynamic than expected at the start of the financial year The veterinary laboratory, despite a basis of comparison which has become high, published quarterly activity in very strong growth. On the stock market, the trend was less positive for Virbac shares since January 1, but the latest publication is now widely welcomed.

A much better dynamic than expected at the start of the financial year Read More »

The normalization of growth is happening at a forced march

The veterinary laboratory is suffering from the downturn in the animal health market as evidenced by its quarterly activity, which was in organic decline. Investors finally welcomed the publication of Vetoquinol’s third quarter sales, with the stock increasing by almost 6% in the session that followed it. The market was clearly anticipating a more marked

The normalization of growth is happening at a forced march Read More »

Scroll to Top